Company Description
Telomir Pharmaceuticals, Inc., a preclinical stage pharmaceutical company, is engaged in the advancement of age reversal science.
The company is developing Telomir 1, a small molecule intended to lengthen and protect telomeres, the DNA end caps of chromosomes that are associated with cellular aging.
Telomir 1 is designed for oral administration and is aimed at extending longevity, improving quality of life, and potentially influencing biological aging.
Telomir Pharmaceuticals is also involved in ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer’s disease, osteoarthritis, and other age related conditions to assess the potential effects of Telomir 1.
The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022.
Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
| Country | United States |
| Founded | 2021 |
| IPO Date | Feb 9, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Erez Aminov |
Contact Details
Address: 100 SE 2nd St., Suite 2000 #1009 Miami, Florida 33131 United States | |
| Phone | 813-864-2558 |
| Website | telomirpharma.com |
Stock Details
| Ticker Symbol | TELO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $7.00 |
| CIK Code | 0001971532 |
| ISIN Number | US87975F1049 |
| Employer ID | 87-2606031 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Erez Aminov | Chairman of the Board and Chief Executive Officer |
| Dr. Francis E. O'Donnell Jr., M.D. | Co-founder, Chief Medical Officer and Special Advisor |
| Michelle Yanez M.B.A. | Chief Financial Officer |
| Dr. Itzchak Angel Ph.D. | Chief Scientific Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 2, 2024 | 8-K | Current Report |
| Nov 21, 2024 | 8-K | Current Report |
| Nov 20, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Sep 27, 2024 | 8-K | Current Report |
| Sep 3, 2024 | 8-K | Current Report |
| Aug 13, 2024 | 10-Q | Quarterly Report |
| Jun 24, 2024 | 8-K | Current Report |
| May 13, 2024 | 10-Q | Quarterly Report |
| Apr 15, 2024 | 8-K | Current Report |